Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study comparing HL02/WBP257 versus Herceptin in combination with docetaxel for HER2-positive metastatic breast cancer
CTR20190665Phase 3Active
- Sponsor
- Hualan Ankang Biotechnology
- Start
- Sep 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of trastuzumab in breast cancer, sponsored by Hualan Ankang Biotechnology. Started Sep 2019; status: active.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20190665.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20190665.